After This Landmark Win, Is CRISPR Therapeutics a Buy?
CRISPR Therapeutics (NASDAQ: CRSP) scored a major win in recent days, earning the world's first regulatory nod for a CRISPR-based gene-editing treatment. The U.S. Food and Drug Administration (FDA) approved Casgevy (developed as exa-cel) for sickle cell disease (SCD) and will consider it for beta thalassemia early next year. A few weeks earlier, U.K. regulators authorized the therapy for both blood disorders.
This represents CRISPR Therapeutics' first commercialized product, meaning revenue growth is just ahead. Since the U.S. approval, though, the company's shares have slipped, falling a little more than 4%. With its first major product approval behind it, has CRISPR Therapeutics said goodbye to its biggest share-performance catalyst, or could this biotech player gain over the long term? Let's find out if the shares are a buy after the company's landmark win.
Image source: Getty Images.
Source Fool.com
